Organic Active Ingredients TRIZ Cases

Deep sequencing identifies low-frequency pathway mutations so mTOR inhibitors can reduce seizures and abnormal neuronal morphology in FCD.

Immune checkpoint inhibitors can trigger severe colitis; CXD101 HDAC inhibition induces neutropenia to reduce neutrophil-driven inflammation.

Low-yield reactions, difficult isolation, and genotoxic impurities challenge CNS compound synthesis; staged purification and protected intermediates address these bottlenecks.

The maleate crystal form targets PD-1/PD-L1 signaling while improving stability under light, humidity, and high temperature.

Multiepoxide and diepoxide cross-linking in concentrated HA improves gel strength and cross-linker utilization while supporting biocompatibility.

A benzimidazole compound inhibits BCR-ABL1 tyrosine kinase activity to address resistant mutations linked to chronic myeloid leukemia relapse.

This case shows how mixed ribonucleotide and 2′-deoxyribonucleotide sequences bind C5a while supporting stability across human and mouse models.

Halouracil substitutions stabilize microRNAs and improve target-mRNA binding to address cancer-treatment toxicity and drug resistance.

Combining a CCK receptor inhibitor with PD1 or CTLA-4 blockade reshapes the PDAC microenvironment and improves immune-cell infiltration.

Bupropion inhibits CYP2D6 metabolism to raise dextromethorphan levels, limit dextrorphan formation, and reduce dosing frequency.

Elocalcitol activates the vitamin D receptor to inhibit NF-κB signaling while addressing visceral fat, lipids, blood pressure, and glucose intolerance.

Costly palivizumab and limited inhibitor applicability motivate small-molecule benzodiazepines for broad-spectrum HRSV prevention and treatment.

HR-deficient cancers can rely on Polθ for backup DNA repair; thiadiazolyl derivatives block its ATP-dependent helicase activity.

Poor solubility and blood-plasma instability limit disulfiram; a saccharide-linked prodrug preserves copper chelation for cancer treatment.

A tetrahydronaphthyridine derivative suppresses melanin production and inflammation, offering a lower-irritation alternative to hydroquinone for melasma.

Inhibiting MTRES1 with small-molecule compositions can reduce neurodegeneration markers in neural cells and support improved cognitive function.

Biomarker assays for SAC activity, ploidy, WGD, and APC/C activity identify tumors most likely to respond to KIF18A inhibitors.

Modified-release oral minoxidil sustains serum levels for hair regrowth while limiting high peak concentrations and related adverse effects.

Controlled crystallization defines a stable Form 1 of deuruxolitinib phosphate, reducing polymorph variability in solubility and bioavailability.

A small-molecule regimen modulates BRG1 and BRM activity to address BAF-complex cancers, suppress tumors, and induce apoptosis.

LH/CG receptor agonists target adipose tissue to reduce fat accumulation and promote thermogenesis in menopausal women.

A continuous-flow process uses tubular reaction and inline quenching to limit hazardous HN3 during drug synthesis.

Conventional liposomes can drive nucleic acids to the liver; tailored lipid ratios redirect delivery toward muscle injection sites.

Human milk oligosaccharides boost sunscreen emulsion SPF, easing reliance on a limited set of approved active agents.

Controlled reductive amination combines defined intermediates, reagents, solvents, and temperatures to improve Compound 1 synthesis.

CFTR misfolding and endoplasmic-reticulum retention impair ion balance; these compounds target protein stability and trafficking.

Solubilized estradiol with micronized or partially solubilized progesterone helps reduce absorption variability and support lower effective dosages.

Quinazoline derivatives replace Amodiaquine’s quinoline skeleton to preserve anti-SARS-CoV-2 activity while addressing toxicity and drug-interaction limits.

Protein-free trehalose culture and supernatant replacement yield a stem-cell secretome that improves muscle mass, strength, and recovery while reducing fibrosis.

Compound I directly modulates cardiac myosin to increase crossbridge formation and contractility without affecting calcium homeostasis.

Benzoxazepin oxazolidinone compounds selectively inhibit mutant PI3Kα, aiming to spare non-mutant cells and reduce gastrointestinal toxicity.

Modified protease inhibitor structures reduce hepatic metabolism while maintaining HIV replication inhibition for less frequent dosing.

SM141 and SM142 use an alternative MPro active-site binding mode to suppress SARS-CoV-2 while lowering cross-resistance risk.

Combining 24-hour subcutaneous levodopa and carbidopa infusion with oral dosing sustains plasma levels and limits motor fluctuations.

These compounds trigger PD-L1 internalization from the cell surface, reducing PD-1 inhibitory signaling and supporting immune responses.

Administering a 15-PGDH inhibitor before renal ischemia-reperfusion injury raises PGE2, supports vasodilation, and helps preserve kidney function.

pH-responsive ionizable lipids help nanoparticles protect mRNA at physiological pH, then support cell entry and RNA release in acidic endosomes.

This case uses decoction, vacuum concentration, and an effervescent suppository to raise local drug concentration while limiting systemic side effects.

Polyvalent molecules stabilize nucleic acids in lipid nanoparticles, helping resist degradation during delivery to target cells.

Conventional assays miss anhydride U; enzymatic synthesis enables precise tRNA detection and quantification with advanced sequencing.

Sodium and ethanolamine salt formation targets HBI-3808 stability and bioavailability while defined XRPD patterns support consistent solid-form characterization.

Measuring IL-6 and TNFα ratios identifies likely non-responders and guides combination therapy for gastrointestinal disease.

Foreign-body responses can cause infusion-site loss and occlusion; heparin, dextran, or rapamycin help sustain insulin delivery for at least 7 days.

Unstable water molecules in the TYK2 binding pocket are displaced to improve inhibitory potency while molecular properties are tuned.

Hybrid RNA-DNA guides pair with Cas12 and donor polynucleotides to improve targeted gene insertion in therapeutic somatic-cell editing.

Amorphous SGLT inhibitors face storage instability; Forms I and II use controlled crystallization to improve stability and solubility.

Smooth RAS surfaces and high GTP affinity hinder small-molecule binding; this compound selectively targets KRAS G12D for potential cancer treatment.

Compounds of Formula I/I′ inhibit SSAO/VAP-1 activity to address NASH-related liver inflammation, fibrosis, and chronic pain.

Traditional CB1 antagonists can suppress basal activity and cause adverse effects; this derivative selectively blocks pathological THC signaling while preserving cAMP pathways.

High JAK-family similarity makes TYK2 selectivity difficult; tailored heterocyclic substituents target TYK2 while limiting off-target effects.

Human milk oligosaccharides address limited specificity by selectively promoting or suppressing growth in targeted intestinal bacteria.

This case uses water and temperature controls plus HPLC testing to limit degradation impurities and preserve clevidipine potency.

A semipermeable coating and osmotic core balance high-dose dexpramipexole release with swallowable tablet weight.

Specific solvent and enhancer ratios support skin penetration and formulation stability while limiting systemic exposure.

This case converts an estrogen receptor antagonist into salts and solid forms to improve stability, flow, and pharmacokinetic performance.

This case uses TGF-β1/TGF-β2 and FGF in an injectable composition to reduce pain and stimulate collagen-based tissue repair.

Phosphorylpurinone TLR7 agonists improve solubility for systemic tumor targeting.

Solvents, gelling agents, and antioxidants support localized mTOR inhibitor delivery across skin layers with reduced systemic absorption.

This case combines UV-blocking plastic packaging, pH control, and filtration to limit AFDX0250 hydrolysis and photodegradation.

This case uses PEG-stabilized staurosporine analog micelles and HSA to limit AAG binding and sustain GBM drug delivery.

Pre-treatment and localized delivery increase RXFP1 receptor density, improving ligand efficacy while limiting systemic side effects.

This case uses combined methyl donors before OPU to improve oocyte quantity and developmental competence for ex vivo fertilization.

Nitrogen purging, pH control, and stabilizers improve pemetrexed liquid stability while simplifying clinical preparation.

A tailored pyrrolo[2,3-d]pyrimidine scaffold targets IRAK4 selectively to reduce IL-6, IL-10, and malignant cell proliferation.

This veterinary composition uses paromomycin sulfate in calves to improve diarrhea, reduce oocyst shedding, and support weight gain.

This case combines platelet-derived extracellular vesicles with lower-dose drugs to sustain immune control and reduce side effects.

This case shows how Formula I compounds broaden BCR-ABL mutation coverage to address T315I and complex-mutant CML resistance.

This case uses ectoine and hydroxyectoine to enhance sirtuin activity and support lung and skin tissue treatment.

Electrostatic nanocomplexes from branched polypeptides protect nucleic acids, support cellular uptake, and limit toxicity.

This case uses a DNA/LNA mixmer oligonucleotide to target miR-132, addressing cardiac remodeling and limited heart-failure efficacy.

This case combines sesquiterpene derivatives with PD-1 antibodies to improve treatment response in low-responsive tumors.

This case combines CAPRIN-1 antibody targeting with EGFR inhibition to enhance immune-cell phagocytosis and address treatment resistance.

This case develops an ammonium salt polymer that binds intestinal bile acids, reduces reabsorption, and supports lipid and liver control.

Crystal form A uses acetone-water crystallization to improve stability and control exposure while preserving TLR8 agonist activity.

Two-step probiotic fermentation improves nutrient bioavailability and reduces antinutrients.

This case adds reducing additives to the adhesive layer, limiting asenapine-N-oxide and preserving patch stability during storage.

Ceramide nanoliposomes encapsulate anticancer agents and induce apoptosis in prostate and head and neck cancer cells.

Selective GABAA γ1 PAMs target γ1-containing receptors to restore GABAergic signaling while avoiding non-selective benzodiazepine sedation.

LPA1 antagonists target fibrotic pathways instead of broad immunosuppression.

This case uses MAS receptor agonists to activate mitophagy pathways, promoting mitochondrial turnover for disease treatment.

Chloride salts, antioxidants, and buffers stabilize bendamustine liquids, keeping total impurities below 5% after 15 months.

Polar C17 and heteroaryl groups improve activity profiles while inhibiting nitric oxide production and modulating signaling.

This case uses a DGAT1 inhibitor to alter fecal composition and reduce opioid-induced constipation without bulk-forming laxatives.

This case shows how chemically modified antisense compounds target MECP2 mRNA to reduce protein levels while limiting toxicity.

Seven-13C vitamin B12 derivatives support accurate biological-sample quantitation using conventional mass spectrometry.

This case uses feijoa extract polyphenols to reduce glucose, lipids, blood pressure, and inflammatory cytokines with lower toxicity.

This fixed-ratio combination targets upstream signaling and cell-cycle pathways to improve efficacy across multiple cancers.

CRISPR editing modifies self-renewal and apoptosis genes to improve T-cell expansion, survival, and CAR-T manufacturing.

Sidewall ammonium-functionalized carbon nanotubes carry NLRP3 siRNA into kidney cells, reducing fibrosis and inflammation in CKD.

This case develops Kv7.2/7.3-selective potentiators to reduce motor neuron excitability while limiting retigabine-related side effects.

A triazine-assisted, telescoped route reduces solvent use and skips intermediate purification while producing high-purity compounds.

A thiazole-containing allosteric compound addresses resistance to ATP-site EGFR inhibitors in multiple mutant forms.

See how crystalline psilocin mucate addresses poor crystallinity and oxidation with improved stability and handling.

This case uses small-molecule APOL1 inhibitors to limit renal toxicity while addressing diseases linked to the high-risk genotype.

A sterile, ready-to-use IV diltiazem solution avoids on-site dilution while supporting extended refrigerated and room-temperature storage.

This case combines opioids with D3R agonists or D1R antagonists to reduce inflammation and fibrosis while stabilizing nerve function.

Explore C4-carbonothioate tryptamines that improve serotonin receptor selectivity and pharmacokinetics for neurological treatments.

Novel cationic lipids combine tailored structures to deliver nucleic acids in serum while improving expression and limiting toxicity.

PLGA-core, chitosan-shell nanoparticles deliver delmopinol and antibiotics over time to inhibit biofilm formation on medical devices.

This case uses 19-norprogesterone compounds with topical or inhaled delivery for tissue-specific TBI treatment and minimal side effects.